Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior
Clearmind Medicine (Nasdaq: CMND) has received a Notice of Allowance from the United States Patent Office for a patent covering its MEAI treatment for binge behavior. This development strengthens the company's intellectual property portfolio and provides additional protection for their novel MEAI-based treatment.
The clinical-stage biotech company, which focuses on developing psychedelic-derived therapeutics for major under-treated health problems, views this patent allowance as a important step in supporting their future success and advancing next-generation psychedelic-derived therapeutics aimed at delivering transformative patient outcomes.
Clearmind Medicine (Nasdaq: CMND) ha ricevuto un Avviso di Concessione dall'Ufficio Brevetti degli Stati Uniti per un brevetto che copre il suo trattamento MEAI per il comportamento da abbuffata. Questo sviluppo rafforza il portafoglio di proprietà intellettuale dell'azienda e offre una protezione aggiuntiva per il loro innovativo trattamento a base di MEAI.
La società biotech in fase clinica, che si concentra sullo sviluppo di terapie derivate da sostanze psichedeliche per gravi problemi di salute poco trattati, considera questa concessione del brevetto un passo importante per supportare il loro successo futuro e promuovere terapie psichedeliche di nuova generazione volte a offrire risultati trasformativi per i pazienti.
Clearmind Medicine (Nasdaq: CMND) ha recibido un Aviso de Concesión por parte de la Oficina de Patentes de Estados Unidos para una patente que cubre su tratamiento MEAI para el comportamiento compulsivo por atracones. Este avance fortalece la cartera de propiedad intelectual de la empresa y brinda protección adicional para su novedoso tratamiento basado en MEAI.
La empresa biotecnológica en fase clínica, que se enfoca en desarrollar terapias derivadas de psicodélicos para problemas de salud graves y poco tratados, considera esta concesión de patente como un paso importante para apoyar su éxito futuro y avanzar en terapias psicodélicas de próxima generación destinadas a ofrecer resultados transformadores para los pacientes.
Clearmind Medicine (나스닥: CMND)은 폭식 행동 치료를 위한 MEAI 관련 특허에 대해 미국 특허청으로부터 허가 통지서를 받았습니다. 이 개발은 회사의 지적 재산권 포트폴리오를 강화하고 혁신적인 MEAI 기반 치료법에 대한 추가 보호를 제공합니다.
임상 단계의 이 바이오테크 기업은 주요 미충족 건강 문제를 위한 사이키델릭 유래 치료제 개발에 주력하고 있으며, 이번 특허 허가는 향후 성공을 지원하고 차세대 사이키델릭 유래 치료제를 발전시키는 중요한 단계로 보고 있습니다. 이는 환자들에게 획기적인 치료 결과를 제공하는 데 목적이 있습니다.
Clearmind Medicine (Nasdaq : CMND) a reçu un avis d'acceptation de l'Office des brevets des États-Unis pour un brevet couvrant son traitement MEAI destiné au comportement de frénésie alimentaire. Ce développement renforce le portefeuille de propriété intellectuelle de l'entreprise et offre une protection supplémentaire pour leur traitement innovant à base de MEAI.
Cette société biotechnologique en phase clinique, spécialisée dans le développement de thérapeutiques dérivées de psychédéliques pour des problèmes de santé majeurs peu traités, considère cette acceptation de brevet comme une étape importante pour soutenir leur succès futur et faire avancer les thérapeutiques psychédéliques de nouvelle génération visant à offrir des résultats transformateurs aux patients.
Clearmind Medicine (Nasdaq: CMND) hat von dem US-Patentamt eine Zulassungsmitteilung für ein Patent erhalten, das seine MEAI-Behandlung für Binge-Verhalten abdeckt. Diese Entwicklung stärkt das geistige Eigentumsportfolio des Unternehmens und bietet zusätzlichen Schutz für ihre neuartige MEAI-basierte Behandlung.
Das klinisch fortgeschrittene Biotechnologieunternehmen, das sich auf die Entwicklung von therapeutischen Mitteln aus Psychedelika für schwer behandelbare Gesundheitsprobleme spezialisiert hat, betrachtet diese Patenterteilung als einen wichtigen Schritt zur Unterstützung ihres zukünftigen Erfolgs und zur Förderung von Psychedelik-therapeutika der nächsten Generation, die transformative Ergebnisse für Patienten liefern sollen.
- Secured US patent allowance for MEAI treatment, strengthening IP protection
- Enhanced competitive position in psychedelic therapeutics space
- Additional protection for binge behavior treatment application
- None.
Vancouver, Canada, April 17, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to its MEAI treatment for binge behavior.
This new US patent provides additional intellectual property protection for the Company’s novel MEAI- based treatment in this indication and further strengthens Clearmind’s intellectual property portfolio.
Dr. Adi Zuloff-Shani, CEO of Clearmind, commented: “This Notice of Allowance further strengthens our unique position in the space and growing intellectual property portfolio and reinforces the potential of our robust MEAI program. Securing foundational patent protection is a vital step in supporting our future success and in driving the development of next-generation psychedelic-derived therapeutics with the potential to deliver transformative outcomes for patients.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses how securing foundational patent protection is a vital step in supporting its future success and in driving the development of next-generation psychedelic-derived therapeutics with the potential to deliver transformative outcomes for patients. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the significance of Clearmind Medicine's (CMND) new patent allowance?
What therapeutic area does Clearmind Medicine's (CMND) MEAI treatment target?
How does the US patent allowance impact Clearmind Medicine's (CMND) market position?
What is the current development stage of Clearmind Medicine's (CMND) MEAI program?
